New Haven, CT, United States of America

Scott Bidlingmaier


Average Co-Inventor Count = 2.7

ph-index = 2

Forward Citations = 24(Granted Patents)


Company Filing History:


Years Active: 1998-2003

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Scott Bidlingmaier: Innovator in Genetic Expression Technologies

Introduction

Scott Bidlingmaier is a notable inventor based in New Haven, CT (US). He has made significant contributions to the field of genetic expression, holding 2 patents that showcase his innovative work. His research focuses on novel genes and vectors that enhance gene expression, which has important implications in biotechnology and medicine.

Latest Patents

Bidlingmaier's latest patents include groundbreaking technologies related to vectors and genes exhibiting increased expression. One patent discloses novel genes and vectors that feature increased expression and unique splicing patterns. These genes can include one or more consensus or near-consensus splice sites that have been corrected. Additionally, the genes may contain introns within coding or noncoding sequences, as well as modified untranslated regions optimized for high levels of tissue-specific expression. Another patent involves the use of viral cis-acting post-transcriptional regulatory sequences, which enhance the export of gene transcripts from the nucleus to the cytoplasm, thereby increasing expression levels of intronless genes.

Career Highlights

Scott Bidlingmaier is currently associated with The Immune Response Corporation, where he continues to advance his research in genetic technologies. His work has the potential to impact various fields, including gene therapy and vaccine development.

Collaborations

Some of his notable coworkers include Charles R. Ill and Jose E. N. Gonzales, who contribute to the collaborative efforts in their research endeavors.

Conclusion

Scott Bidlingmaier's innovative work in genetic expression technologies highlights his role as a leading inventor in the field. His patents reflect a commitment to advancing scientific knowledge and improving therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…